Search

Your search keyword '"Schnell, Gretja"' showing total 180 results
Start Over Author "Schnell, Gretja"
180 results on '"Schnell, Gretja"'

1. Neutralization, effector function and immune imprinting of Omicron variants

Author

Addetia, Amin, Piccoli, Luca, Case, James Brett, Park, Young-Jun, Beltramello, Martina, Guarino, Barbara, Dang, Ha, de Melo, Guilherme Dias, Pinto, Dora, Sprouse, Kaitlin, Scheaffer, Suzanne M., Bassi, Jessica, Silacci-Fregni, Chiara, Muoio, Francesco, Dini, Marco, Vincenzetti, Lucia, Acosta, Rima, Johnson, Daisy, Subramanian, Sambhavi, Saliba, Christian, Giurdanella, Martina, Lombardo, Gloria, Leoni, Giada, Culap, Katja, McAlister, Carley, Rajesh, Anushka, Dellota, Jr, Exequiel, Zhou, Jiayi, Farhat, Nisar, Bohan, Dana, Noack, Julia, Chen, Alex, Lempp, Florian A., Quispe, Joel, Kergoat, Lauriane, Larrous, Florence, Cameroni, Elisabetta, Whitener, Bradley, Giannini, Olivier, Cippà, Pietro, Ceschi, Alessandro, Ferrari, Paolo, Franzetti-Pellanda, Alessandra, Biggiogero, Maira, Garzoni, Christian, Zappi, Stephanie, Bernasconi, Luca, Kim, Min Jeong, Rosen, Laura E., Schnell, Gretja, Czudnochowski, Nadine, Benigni, Fabio, Franko, Nicholas, Logue, Jennifer K., Yoshiyama, Courtney, Stewart, Cameron, Chu, Helen, Bourhy, Hervé, Schmid, Michael A., Purcell, Lisa A., Snell, Gyorgy, Lanzavecchia, Antonio, Diamond, Michael S., Corti, Davide, and Veesler, David

Published
2023
Full Text
View/download PDF

2. Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab

Author

Agostini, Maria L, primary, Schnell, Gretja, additional, Iulio, Julia di, additional, Kohli, Anita, additional, Shapiro, Adrienne E, additional, Sarkis, Elias H, additional, Givens, Naomi, additional, Peppercorn, Amanda, additional, Skingsley, Andrew, additional, Gaffney, Leah A, additional, Aldinger, Melissa, additional, Hebner, Christy M, additional, and Cathcart, Andrea L, additional

Published
2024
Full Text
View/download PDF

3. Phenotypic Correlates of HIV-1 Macrophage Tropism

Author

Arrildt, Kathryn T, LaBranche, Celia C, Joseph, Sarah B, Dukhovlinova, Elena N, Graham, William D, Ping, Li-Hua, Schnell, Gretja, Sturdevant, Christa B, Kincer, Laura P, Mallewa, Macpherson, Heyderman, Robert S, Van Rie, Annelies, Cohen, Myron S, Spudich, Serena, Price, Richard W, Montefiori, David C, and Swanstrom, Ronald

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Immunization, Sexually Transmitted Infections, HIV/AIDS, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, CD4 Antigens, CD4-Positive T-Lymphocytes, Cell Line, Tumor, HEK293 Cells, HIV Envelope Protein gp120, HIV Envelope Protein gp160, HIV Envelope Protein gp41, HIV Infections, HIV-1, Humans, Macrophages, Receptors, CCR5, Recombinant Proteins, Viral Tropism, Virus Internalization, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

UnlabelledHIV-1 is typically CCR5 using (R5) and T cell tropic (T-tropic), targeting memory CD4(+) T cells throughout acute and chronic infections. However, viruses can expand into alternative cells types. Macrophage-tropic (M-tropic) HIV-1 variants have evolved to infect macrophages, which have only low levels of surface CD4. Most M-tropic variants have been isolated from the central nervous system during late-stage chronic infection. We used the HIV-1 env genes of well-defined, subject-matched M-tropic and T-tropic viruses to characterize the phenotypic features of the M-tropic Env protein. We found that, compared to T-tropic viruses, M-tropic viruses infect monocyte-derived macrophages (MDMs) on average 28-fold more efficiently, use low-density CD4 more efficiently, have increased sensitivity to soluble CD4 (sCD4), and show trends toward sensitivity to some CD4 binding site antibodies but no difference in sensitivity to antibodies targeting the CD4-bound conformation. M-tropic viruses also displayed a trend toward resistance to neutralization by monoclonal antibodies targeting the V1/V2 region of Env, suggesting subtle changes in Env protein conformation. The paired M- and T-tropic viruses did not differ in autologous serum neutralization, temperature sensitivity, entry kinetics, intrinsic infectivity, or Env protein incorporation. We also examined viruses with modestly increased CD4 usage. These variants have significant sensitivity to sCD4 and may represent evolutionary intermediates. CD4 usage is strongly correlated with infectivity of MDMs over a wide range of CD4 entry phenotypes. These data suggest that emergence of M-tropic HIV-1 includes multiple steps in which a phenotype of increased sensitivity to sCD4 and enhanced CD4 usage accompany subtle changes in Env conformation.ImportanceHIV-1 typically replicates in CD4(+) T cells. However, HIV-1 can evolve to infect macrophages, especially within the brain. Understanding how CCR5-using macrophage-tropic viruses evolve and differ from CCR5-using T cell-tropic viruses may provide insights into viral evolution and pathogenesis within the central nervous system. We characterized the HIV-1 env viral entry gene from subject-matched macrophage-tropic and T cell-tropic viruses to identify entry features of macrophage-tropic viruses. We observed several differences between T cell-tropic and macrophage-tropic Env proteins, including functional differences with host CD4 receptor engagement and possible changes in the CD4 binding site and V1/V2 region. We also identified viruses with phenotypes between that of "true" macrophage-tropic and T cell-tropic viruses, which may represent evolutionary intermediates in a multistep process to macrophage tropism.

Published
2015

4. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.

Author

Sturdevant, Christa Buckheit, Joseph, Sarah B, Schnell, Gretja, Price, Richard W, Swanstrom, Ronald, and Spudich, Serena

Subjects
Central Nervous System, Cell Line, Humans, HIV-1, AIDS Dementia Complex, RNA, Viral, Virus Replication, Adult, Middle Aged, Female, Male, Viral Tropism, Pediatric AIDS, Neurosciences, Infectious Diseases, Clinical Research, HIV/AIDS, Mental Health, Pediatric, 2.2 Factors relating to physical environment, 2.1 Biological and endogenous factors, Infection, RNA, Viral, Virology, Microbiology, Immunology, Medical Microbiology
Abstract

Compartmentalized HIV-1 replication within the central nervous system (CNS) likely provides a foundation for neurocognitive impairment and a potentially important tissue reservoir. The timing of emergence and character of this local CNS replication has not been defined in a population of subjects. We examined the frequency of elevated cerebrospinal fluid (CSF) HIV-1 RNA concentration, the nature of CSF viral populations compared to the blood, and the presence of a cellular inflammatory response (with the potential to bring infected cells into the CNS) using paired CSF and blood samples obtained over the first two years of infection from 72 ART-naïve subjects. Using single genome amplification (SGA) and phylodynamics analysis of full-length env sequences, we compared CSF and blood viral populations in 33 of the 72 subjects. Independent HIV-1 replication in the CNS (compartmentalization) was detected in 20% of sample pairs analyzed by SGA, or 7% of all sample pairs, and was exclusively observed after four months of infection. In subjects with longitudinal sampling, 30% showed evidence of CNS viral replication or pleocytosis/inflammation in at least one time point, and in approximately 16% of subjects we observed evolving CSF/CNS compartmentalized viral replication and/or a marked CSF inflammatory response at multiple time points suggesting an ongoing or recurrent impact of the infection in the CNS. Two subjects had one of two transmitted lineages (or their recombinant) largely sequestered within the CNS shortly after transmission, indicating an additional mechanism for establishing early CNS replication. Transmitted variants were R5 T cell-tropic. Overall, examination of the relationships between CSF viral populations, blood and CSF HIV-1 RNA concentrations, and inflammatory responses suggested four distinct states of viral population dynamics, with associated mechanisms of local viral replication and the early influx of virus into the CNS. This study considerably enhances the generalizability of our results and greatly expands our knowledge of the early interactions of HIV-1 in the CNS.

Published
2015

6. Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study

Author

Subramanian, Sambhavi, primary, Schnell, Gretja, additional, Iulio, Julia di, additional, Gupta, Anil K, additional, Shapiro, Adrienne E, additional, Sarkis, Elias H, additional, Lopuski, Amanda, additional, Peppercorn, Amanda, additional, Aldinger, Melissa, additional, Hebner, Christy M, additional, and Cathcart, Andrea L, additional

Published
2023
Full Text
View/download PDF

7. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

Author

Schnell, Gretja, Spudich, Serena, Harrington, Patrick, Price, Richard W, and Swanstrom, Ronald

Subjects
Central Nervous System, CD4-Positive T-Lymphocytes, Macrophages, Blood, Cerebrospinal Fluid, Humans, HIV-1, HIV Infections, AIDS Dementia Complex, Leukocytosis, Antiviral Agents, Cell Aging, Half-Life, Genetic Variation, Cellular Senescence, Virology, Microbiology, Immunology, Medical Microbiology
Abstract

Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) shortly after systemic infection and can result in the subsequent development of HIV-1-associated dementia (HAD) in a subset of infected individuals. Genetically compartmentalized virus in the CNS is associated with HAD, suggesting autonomous viral replication as a factor in the disease process. We examined the source of compartmentalized HIV-1 in the CNS of subjects with HIV-1-associated neurological disease and in asymptomatic subjects who were initiating antiretroviral therapy. The heteroduplex tracking assay (HTA), targeting the variable regions of env, was used to determine which HIV-1 genetic variants in the cerebrospinal fluid (CSF) were compartmentalized and which variants were shared with the blood plasma. We then measured the viral decay kinetics of individual variants after the initiation of antiretroviral therapy. Compartmentalized HIV-1 variants in the CSF of asymptomatic subjects decayed rapidly after the initiation of antiretroviral therapy, with a mean half-life of 1.57 days. Rapid viral decay was also measured for CSF-compartmentalized variants in four HAD subjects (t(1/2) mean = 2.27 days). However, slow viral decay was measured for CSF-compartmentalized variants from an additional four subjects with neurological disease (t(1/2) range = 9.85 days to no initial decay). The slow decay detected for CSF-compartmentalized variants was not associated with poor CNS drug penetration, drug resistant virus in the CSF, or the presence of X4 virus genotypes. We found that the slow decay measured for CSF-compartmentalized variants in subjects with neurological disease was correlated with low peripheral CD4 cell count and reduced CSF pleocytosis. We propose a model in which infiltrating macrophages replace CD4(+) T cells as the primary source of productive viral replication in the CNS to maintain high viral loads in the CSF in a substantial subset of subjects with HAD.

Published
2009

8. Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial

Author

Moya, Jaynier, primary, Temech, Marisol, additional, Parra, Sergio, additional, Juarez, Erick, additional, Hernandez-Loy, Reinaldo, additional, Moises Gutierrez, Juan C., additional, Diaz, Jorge, additional, Hussain, Rubaba, additional, Segal, Scott, additional, Xu, Claire, additional, Skingsley, Andrew, additional, Schnell, Gretja, additional, El-Zailik, Asma, additional, Sager, Jennnifer E., additional, Aldinger, Melissa, additional, Alexander, Elizabeth L., additional, and Acloque, Gerard, additional

Published
2023
Full Text
View/download PDF

10. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

Author

Addetia, Amin, primary, Piccoli, Luca, additional, Case, James Brett, additional, Park, Young-Jun, additional, Beltramello, Martina, additional, Guarino, Barbara, additional, Dang, Ha, additional, Pinto, Dora, additional, Scheaffer, Suzanne M., additional, Sprouse, Kaitlin, additional, Bassi, Jessica, additional, Silacci-Fregni, Chiara, additional, Muoio, Francesco, additional, Dini, Marco, additional, Vincenzetti, Lucia, additional, Acosta, Rima, additional, Johnson, Daisy, additional, Subramanian, Sambhavi, additional, Saliba, Christian, additional, Giurdanella, Martina, additional, Lombardo, Gloria, additional, Leoni, Giada, additional, Culap, Katja, additional, McAlister, Carley, additional, Rajesh, Anushka, additional, Dellota, Exequiel, additional, Zhou, Jiayi, additional, Farhat, Nisar, additional, Bohan, Dana, additional, Noack, Julia, additional, Lempp, Florian A., additional, Cameroni, Elisabetta, additional, Whitener, Bradley, additional, Giannini, Olivier, additional, Ceschi, Alessandro, additional, Ferrari, Paolo, additional, Franzetti-Pellanda, Alessandra, additional, Biggiogero, Maira, additional, Garzoni, Christian, additional, Zappi, Stephanie, additional, Bernasconi, Luca, additional, Kim, Min Jeong, additional, Schnell, Gretja, additional, Czudnochowski, Nadine, additional, Franko, Nicholas, additional, Logue, Jennifer K., additional, Yoshiyama, Courtney, additional, Stewart, Cameron, additional, Chu, Helen, additional, Schmid, Michael A., additional, Purcell, Lisa A., additional, Snell, Gyorgy, additional, Lanzavecchia, Antonio, additional, Diamond, Michael S., additional, Corti, Davide, additional, and Veesler, David, additional

Published
2023
Full Text
View/download PDF

11. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Author

Hézode, Christophe, Asselah, Tarik, Reddy, K Rajender, Hassanein, Tarek, Berenguer, Marina, Fleischer-Stepniewska, Katarzyna, Marcellin, Patrick, Hall, Coleen, Schnell, Gretja, Pilot-Matias, Tami, Mobashery, Niloufar, Redman, Rebecca, Vilchez, Regis A, and Pol, Stanislas

Published
2015
Full Text
View/download PDF

12. 1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19

Author

Gupta, Anil K, primary, Perez-Rodríguez, Maria Teresa, additional, Gonzalez-Rojas, Yaneicy, additional, Ramgopal, Moti, additional, Free, Almena, additional, Han, Jennifer, additional, Moore, Jennifer, additional, Banerjee, Rudrani, additional, Yates, Phillip, additional, Walker, Jill, additional, Schnell, Gretja, additional, Connolly, Mary Beth, additional, Cathcart, Andrea L, additional, Imber, Varsha, additional, Anselm, Rabia, additional, Winograd, Lindsay, additional, Haeusser, Nancy, additional, Segal, Scott, additional, Skingsley, Andrew, additional, Aldinger, Melissa, additional, Peppercorn, Amanda, additional, and Moya, Jaynier, additional

Published
2022
Full Text
View/download PDF

13. 1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab

Author

Agostini, Maria L, primary, Schnell, Gretja, additional, di Iulio, Julia, additional, Kohli, Anita, additional, Shapiro, Adrienne E, additional, Sarkis, Elias H, additional, Inman, Dave, additional, Peppercorn, Amanda, additional, Skingsley, Andrew, additional, Gaffney, Leah A, additional, Aldinger, Melissa, additional, Hebner, Christy M, additional, and Cathcart, Andrea L, additional

Published
2022
Full Text
View/download PDF

15. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Author

Park, Young-Jun, primary, Pinto, Dora, additional, Walls, Alexandra C., additional, Liu, Zhuoming, additional, De Marco, Anna, additional, Benigni, Fabio, additional, Zatta, Fabrizia, additional, Silacci-Fregni, Chiara, additional, Bassi, Jessica, additional, Sprouse, Kaitlin R., additional, Addetia, Amin, additional, Bowen, John E., additional, Stewart, Cameron, additional, Giurdanella, Martina, additional, Saliba, Christian, additional, Guarino, Barbara, additional, Schmid, Michael A., additional, Franko, Nicholas M., additional, Logue, Jennifer K., additional, Dang, Ha V., additional, Hauser, Kevin, additional, di Iulio, Julia, additional, Rivera, William, additional, Schnell, Gretja, additional, Rajesh, Anushka, additional, Zhou, Jiayi, additional, Farhat, Nisar, additional, Kaiser, Hannah, additional, Montiel-Ruiz, Martin, additional, Noack, Julia, additional, Lempp, Florian A., additional, Janer, Javier, additional, Abdelnabi, Rana, additional, Maes, Piet, additional, Ferrari, Paolo, additional, Ceschi, Alessandro, additional, Giannini, Olivier, additional, de Melo, Guilherme Dias, additional, Kergoat, Lauriane, additional, Bourhy, Hervé, additional, Neyts, Johan, additional, Soriaga, Leah, additional, Purcell, Lisa A., additional, Snell, Gyorgy, additional, Whelan, Sean P. J., additional, Lanzavecchia, Antonio, additional, Virgin, Herbert W., additional, Piccoli, Luca, additional, Chu, Helen Y., additional, Pizzuto, Matteo Samuele, additional, Corti, Davide, additional, and Veesler, David, additional

Published
2022
Full Text
View/download PDF

18. Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.

Author

Moya, Jaynier, Temech, Marisol, Parra, Sergio, Juarez, Erick, Hernandez-Loy, Reinaldo, Gutierrez, Juan C Moises, Diaz, Jorge, Hussain, Rubaba, Segal, Scott, Xu, Claire, Skingsley, Andrew, Schnell, Gretja, El-Zailik, Asma, Sager, Jennifer E, Aldinger, Melissa, Alexander, Elizabeth L, and Acloque, Gerard

Subjects
COVID-19, VIROLOGY, CLINICAL trials, COUGH, PHARMACOKINETICS, VIRAL load, MYOCARDIAL infarction
Abstract

Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk for disease progression. Methods This was an open-label, single-arm substudy of phase 3 COMET-TAIL (NCT04913675) assessing the safety and tolerability of a 2000 mg IV dose of sotrovimab. Symptomatic patients (aged ≥18 years) with COVID-19 at high risk for progression were enrolled from June 30 through July 11, 2022, when Omicron BA.5, BA.2.12.1, and BA.4 were the predominant circulating variants in the United States. The primary end point was the occurrence of adverse events (AEs), serious AEs (SAEs), AEs of special interest, and COVID-19 disease-related events (DREs) through day 8. Safety, pharmacokinetics, viral load, and hospitalization >24 hours for acute management of illness or death through day 29 were assessed. Results All participants (n = 81) were Hispanic, 58% were female, and 51% were aged ≥55 years. Through day 8, no AEs, including infusion-related reactions or hypersensitivity, were reported; 2 participants reported DREs (mild cough, n = 2). One SAE (acute myocardial infarction), which was considered unrelated to sotrovimab or COVID-19 by the investigator, occurred on day 27 and was the only hospitalization reported. Maximum serum concentration (geometric mean) was 745.9 µg/mL. Viral load decreased from baseline through day 29; only 2 (3%) participants had a persistently high viral load (≥4.1 log10 copies/mL) at day 8. Conclusions Two thousand milligrams of IV sotrovimab was well tolerated, with no safety signals observed. Trial registration ClinicalTrials.gov Identifier: NCT04913675. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Author

Park, Young-Jun, Pinto, Dora, Walls, Alexandra C, Liu, Zhuoming, De Marco, Anna, Benigni, Fabio, Zatta, Fabrizia, Silacci-Fregni, Chiara, Bassi, Jessica, Sprouse, Kaitlin R, Addetia, Amin, Bowen, John E, Stewart, Cameron, Giurdanella, Martina, Saliba, Christian, Guarino, Barbara, Schmid, Michael A, Franko, Nicholas M, Logue, Jennifer K, Dang, Ha V, Hauser, Kevin, di Iulio, Julia, Rivera, William, Schnell, Gretja, Rajesh, Anushka, Zhou, Jiayi, Farhat, Nisar, Kaiser, Hannah, Montiel-Ruiz, Martin, Noack, Julia, et al, Ferrari, Paolo, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, Giannini, Olivier, De Melo, Guilherme Dias, Lanzavecchia, Antonio, Piccoli, Luca, Pizzuto, Matteo Samuele, Corti, Davide; https://orcid.org/0000-0002-5797-1364, Park, Young-Jun, Pinto, Dora, Walls, Alexandra C, Liu, Zhuoming, De Marco, Anna, Benigni, Fabio, Zatta, Fabrizia, Silacci-Fregni, Chiara, Bassi, Jessica, Sprouse, Kaitlin R, Addetia, Amin, Bowen, John E, Stewart, Cameron, Giurdanella, Martina, Saliba, Christian, Guarino, Barbara, Schmid, Michael A, Franko, Nicholas M, Logue, Jennifer K, Dang, Ha V, Hauser, Kevin, di Iulio, Julia, Rivera, William, Schnell, Gretja, Rajesh, Anushka, Zhou, Jiayi, Farhat, Nisar, Kaiser, Hannah, Montiel-Ruiz, Martin, Noack, Julia, et al, Ferrari, Paolo, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, Giannini, Olivier, De Melo, Guilherme Dias, Lanzavecchia, Antonio, Piccoli, Luca, Pizzuto, Matteo Samuele, and Corti, Davide; https://orcid.org/0000-0002-5797-1364

Abstract

SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development.

Published
2022

20. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Author

Park, Young-Jun; https://orcid.org/0000-0003-2901-6949, Pinto, Dora, Walls, Alexandra C; https://orcid.org/0000-0002-9636-8330, Liu, Zhuoming; https://orcid.org/0000-0001-8198-0976, De Marco, Anna; https://orcid.org/0000-0001-9641-4838, Benigni, Fabio; https://orcid.org/0000-0002-1974-5606, Zatta, Fabrizia; https://orcid.org/0000-0003-4945-8058, Silacci-Fregni, Chiara, Bassi, Jessica; https://orcid.org/0000-0002-4723-6892, Sprouse, Kaitlin R; https://orcid.org/0000-0003-0007-2226, Addetia, Amin; https://orcid.org/0000-0001-6703-3841, Bowen, John E; https://orcid.org/0000-0003-3590-9727, Stewart, Cameron; https://orcid.org/0000-0002-2786-6256, Giurdanella, Martina, Saliba, Christian; https://orcid.org/0000-0003-0100-6976, Guarino, Barbara; https://orcid.org/0000-0003-3759-3252, Schmid, Michael A; https://orcid.org/0000-0002-1137-9322, Franko, Nicholas M; https://orcid.org/0000-0001-8165-6332, Logue, Jennifer K; https://orcid.org/0000-0002-7889-8960, Dang, Ha V; https://orcid.org/0000-0003-1173-9241, Hauser, Kevin, di Iulio, Julia; https://orcid.org/0000-0001-9343-127X, Rivera, William, Schnell, Gretja, Rajesh, Anushka, Zhou, Jiayi; https://orcid.org/0000-0002-4231-3422, Farhat, Nisar; https://orcid.org/0000-0003-0905-7479, Kaiser, Hannah; https://orcid.org/0000-0002-3991-7401, Montiel-Ruiz, Martin; https://orcid.org/0000-0001-6200-9578, Noack, Julia; https://orcid.org/0000-0002-9113-8181, et al, Ferrari, Paolo, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, Giannini, Olivier, de Melo, Guilherme Dias, Lanzavecchia, Antonio, Piccoli, Luca, Pizzuto, Matteo Samuele, Corti, Davide; https://orcid.org/0000-0002-5797-1364, Park, Young-Jun; https://orcid.org/0000-0003-2901-6949, Pinto, Dora, Walls, Alexandra C; https://orcid.org/0000-0002-9636-8330, Liu, Zhuoming; https://orcid.org/0000-0001-8198-0976, De Marco, Anna; https://orcid.org/0000-0001-9641-4838, Benigni, Fabio; https://orcid.org/0000-0002-1974-5606, Zatta, Fabrizia; https://orcid.org/0000-0003-4945-8058, Silacci-Fregni, Chiara, Bassi, Jessica; https://orcid.org/0000-0002-4723-6892, Sprouse, Kaitlin R; https://orcid.org/0000-0003-0007-2226, Addetia, Amin; https://orcid.org/0000-0001-6703-3841, Bowen, John E; https://orcid.org/0000-0003-3590-9727, Stewart, Cameron; https://orcid.org/0000-0002-2786-6256, Giurdanella, Martina, Saliba, Christian; https://orcid.org/0000-0003-0100-6976, Guarino, Barbara; https://orcid.org/0000-0003-3759-3252, Schmid, Michael A; https://orcid.org/0000-0002-1137-9322, Franko, Nicholas M; https://orcid.org/0000-0001-8165-6332, Logue, Jennifer K; https://orcid.org/0000-0002-7889-8960, Dang, Ha V; https://orcid.org/0000-0003-1173-9241, Hauser, Kevin, di Iulio, Julia; https://orcid.org/0000-0001-9343-127X, Rivera, William, Schnell, Gretja, Rajesh, Anushka, Zhou, Jiayi; https://orcid.org/0000-0002-4231-3422, Farhat, Nisar; https://orcid.org/0000-0003-0905-7479, Kaiser, Hannah; https://orcid.org/0000-0002-3991-7401, Montiel-Ruiz, Martin; https://orcid.org/0000-0001-6200-9578, Noack, Julia; https://orcid.org/0000-0002-9113-8181, et al, Ferrari, Paolo, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, Giannini, Olivier, de Melo, Guilherme Dias, Lanzavecchia, Antonio, Piccoli, Luca, Pizzuto, Matteo Samuele, and Corti, Davide; https://orcid.org/0000-0002-5797-1364

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant–neutralizing antibody that is a strong candidate for clinical development.

Published
2022

21. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir

Author

Wang, Gary P., primary, Schnell, Gretja L., additional, Kort, Jens J., additional, Sidhu, Gurjit S., additional, Schuster, Layla, additional, Tripathi, Rakesh L., additional, Larsen, Lois, additional, Michael, Larry C., additional, Bergquist, Ken, additional, Magee, Ashley, additional, Patel, Chandni B., additional, Whitlock, Joan A., additional, Tamashiro, Ryan, additional, Peter, Joy A., additional, Fried, Michael W., additional, and Nelson, David R., additional

Published
2021
Full Text
View/download PDF

22. Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

Author

Sulkowski, Mark S., Eron, Joseph J., Wyles, David, Trinh, Roger, Lalezari, Jay, Wang, Chia, Slim, Jihad, Bhatti, Laveeza, Gathe, Joseph, Ruane, Peter J., Elion, Richard, Bredeek, Fritz, Brennan, Robert, Blick, Gary, Khatri, Amit, Gibbons, Krystal, Hu, Yiran B., Fredrick, Linda, Schnell, Gretja, Pilot-Matias, Tami, Tripathi, Rakesh, Da Silva-Tillmann, Barbara, McGovern, Barbara, Campbell, Andrew L., and Podsadecki, Thomas

Published
2015
Full Text
View/download PDF

24. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies

Author

Yao, Betty B., primary, Fredrick, Linda M., additional, Schnell, Gretja, additional, Kowdley, Kris V., additional, Kwo, Paul Y., additional, Poordad, Fred, additional, Nguyen, Kinh, additional, Lee, Samuel S., additional, George, Christophe, additional, Wong, Florence, additional, Gane, Edward, additional, Abergel, Armand, additional, Spearman, Catherine W., additional, Nguyen, Tuan, additional, Hung Le, Manh, additional, Pham, Thuy TT., additional, Mensa, Federico, additional, and Asselah, Tarik, additional

Published
2020
Full Text
View/download PDF

25. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Author

Brown, Robert S., primary, Buti, Maria, additional, Rodrigues, Lino, additional, Chulanov, Vladimir, additional, Chuang, Wan-Long, additional, Aguilar, Humberto, additional, Horváth, Gábor, additional, Zuckerman, Elimelech, additional, Carrion, Barbara Rosado, additional, Rodriguez-Perez, Federico, additional, Urbánek, Petr, additional, Abergel, Armand, additional, Cohen, Eric, additional, Lovell, Sandra S., additional, Schnell, Gretja, additional, Lin, Chih-Wei, additional, Zha, Jiuhong, additional, Wang, Stanley, additional, Trinh, Roger, additional, Mensa, Federico J., additional, Burroughs, Margaret, additional, and Felizarta, Franco, additional

Published
2020
Full Text
View/download PDF

26. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders

Author

Fuchs, Michael, primary, Monto, Alexander, additional, Bräu, Norbert, additional, Charafeddine, Mariem, additional, Schmidt, Warren, additional, Kozal, Michael, additional, Naggie, Susanna, additional, Cheung, Ramsey, additional, Schnell, Gretja, additional, Yu, Yao, additional, Richards, Kristine, additional, Mullally, Victoria, additional, Cohen, Daniel E., additional, and Toro, Doris, additional

Published
2020
Full Text
View/download PDF

27. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Author

Lawitz, Eric, primary, Flisiak, Robert, additional, Abunimeh, Manal, additional, Sise, Meghan E., additional, Park, Jun Y., additional, Kaskas, Marwan, additional, Bruchfeld, Annette, additional, Wörns, Marcus‐Alexander, additional, Aglitti, Andrea, additional, Zamor, Philippe J., additional, Xue, Zhenyi, additional, Schnell, Gretja, additional, Jalundhwala, Yash J., additional, Porcalla, Ariel, additional, Mensa, Federico J., additional, and Persico, Marcello, additional

Published
2019
Full Text
View/download PDF

30. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).

Author

UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/ECLI - Pôle d'Essais cliniques, Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Yves, Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, Jose Luis, Bruno, Savino, Schnell, Gretja, Qaqish, Roula, Redman, Rebecca, Pilot-Matias, Tami, Kopecky-Bromberg, Sarah, Yu, Yao, Mobashery, Niloufar, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/ECLI - Pôle d'Essais cliniques, Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Yves, Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, Jose Luis, Bruno, Savino, Schnell, Gretja, Qaqish, Roula, Redman, Rebecca, Pilot-Matias, Tami, Kopecky-Bromberg, Sarah, Yu, Yao, and Mobashery, Niloufar

Abstract

AGATE-I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and 16 weeks' treatment with a combination of two direct-acting antivirals, ombitasvir and paritaprevir (codosed with ritonavir), plus ribavirin. Part II, reported here, extended the trial to include a 24-week treatment arm to fully assess treatment duration in patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis. Enrollment took place between June and November of 2015. Treatment-naive and interferon-experienced patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis were enrolled into Arm C; patients previously treated with a sofosbuvir-based regimen were enrolled into Arm D. All patients received a 24-week treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin. The primary outcome was the proportion of patients with a sustained virologic response (hepatitis C virus RNA < 25 IU/mL) at posttreatment week 12 in the intention-to-treat population. The safety population included all patients who received at least one dose of study drug. In total, 64 patients were enrolled into AGATE-I Part II. Sustained virologic response at posttreatment week 12 was achieved in 57 of 61 patients (93.4%; 97.5% confidence interval, 92.6-97.7) in Arm C and 3 of 3 patients (100%) in Arm D. Two patients were missing SVR12 data, and two prematurely discontinued treatment. The most common adverse events for Arm C were fatigue (16 [26%]) and asthenia (15 [25%]). Results were comparable with those reported in Part I. AGATE-I Part II indicates that extending treatment beyond 12 weeks in genotype 4-infected patients with compensated cirrhosis does not offer additional benefit.

Published
2019

31. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)

Author

Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Y., Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, José Luís Uis J.L., Bruno, Savino, Schnell, Gretja, Qaqish, Roula R.B., Redman, Rebecca, Pilot-Matias, Tami, Kopecky-Bromberg, Sarah, Yu, Yao, Mobashery, Niloufar, Asselah, Tarik, Alami, Negar Niki, Moreno, Christophe, Pol, Stanislas, Karatapanis, Stylianos, Gschwantler, Michael, Horsmans, Y., Elefsiniotis, Ioannis, Larrey, Dominique, Ferrari, Carlo, Rizzetto, Mario, Orlandini, Alessandra, Calleja, José Luís Uis J.L., Bruno, Savino, Schnell, Gretja, Qaqish, Roula R.B., Redman, Rebecca, Pilot-Matias, Tami, Kopecky-Bromberg, Sarah, Yu, Yao, and Mobashery, Niloufar

Abstract

Background and Aims: AGATE-I Part I previously reported high sustained virologic response rates in hepatitis C genotype 4 patients with cirrhosis, with 12 and 16 weeks' treatment with a combination of two direct-acting antivirals, ombitasvir and paritaprevir (codosed with ritonavir), plus ribavirin. Part II, reported here, extended the trial to include a 24-week treatment arm to fully assess treatment duration in patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis. Methods: Enrollment took place between June and November of 2015. Treatment-naive and interferon-experienced patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis were enrolled into Arm C; patients previously treated with a sofosbuvir-based regimen were enrolled into Arm D. All patients received a 24-week treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin. The primary outcome was the proportion of patients with a sustained virologic response (hepatitis C virus RNA < 25 IU/mL) at posttreatment week 12 in the intention-to-treat population. The safety population included all patients who received at least one dose of study drug. Results: In total, 64 patients were enrolled into AGATE-I Part II. Sustained virologic response at posttreatment week 12 was achieved in 57 of 61 patients (93.4%; 97.5% confidence interval, 92.6-97.7) in Arm C and 3 of 3 patients (100%) in Arm D. Two patients were missing SVR12 data, and two prematurely discontinued treatment. The most common adverse events for Arm C were fatigue (16 [26%]) and asthenia (15 [25%]). Results were comparable with those reported in Part I. Conclusions: AGATE-I Part II indicates that extending treatment beyond 12 weeks in genotype 4–infected patients with compensated cirrhosis does not offer additional benefit., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

32. IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study

Author

Brown, Robert S, primary, Hezode, Christopher, additional, Wang, Stanley, additional, Buti, Maria, additional, Chuang, Wan-Long, additional, Aguilar, Humberto, additional, Horvath, Gabor, additional, Carrion, Barbara Rosado, additional, Rodriguez-Perez, Federico, additional, Cohen, Eric, additional, Hu, Yiran B, additional, Schnell, Gretja, additional, Lin, Chih-Wei, additional, Rodrigues, Lino, additional, Trinh, Roger, additional, and Mensa, Federico J, additional

Published
2019
Full Text
View/download PDF

35. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

Author

Asselah, Tarik, primary, Alami, Negar Niki, additional, Moreno, Christophe, additional, Pol, Stanislas, additional, Karatapanis, Stylianos, additional, Gschwantler, Michael, additional, Horsmans, Yves, additional, Elefsiniotis, Ioannis, additional, Larrey, Dominique, additional, Ferrari, Carlo, additional, Rizzetto, Mario, additional, Orlandini, Alessandra, additional, Calleja, Jose Luis, additional, Bruno, Savino, additional, Schnell, Gretja, additional, Qaqish, Roula, additional, Redman, Rebecca, additional, Pilot‐Matias, Tami, additional, Kopecky‐Bromberg, Sarah, additional, Yu, Yao, additional, and Mobashery, Niloufar, additional

Published
2019
Full Text
View/download PDF

36. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.

Author

Lawitz, Eric, Flisiak, Robert, Abunimeh, Manal, Sise, Meghan E., Park, Jun Y., Kaskas, Marwan, Bruchfeld, Annette, Wörns, Marcus‐Alexander, Aglitti, Andrea, Zamor, Philippe J., Xue, Zhenyi, Schnell, Gretja, Jalundhwala, Yash J., Porcalla, Ariel, Mensa, Federico J., and Persico, Marcello

Subjects
CHRONIC hepatitis C, CHRONIC kidney failure, HEPATITIS C virus
Abstract

Background and Aims: Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end‐stage renal disease (ESRD). Previously available direct‐acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods: EXPEDITION‐5 is a phase 3 study to evaluate efficacy and safety of the fixed‐dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experience. The primary efficacy endpoint was percentage of patients with sustained virologic response at 12 weeks post‐treatment (SVR12). Results: Among the 101 patients enrolled in the study, 24% had predialysis CKD and 76% were on dialysis. Eighty‐four patients were treated with G/P for 8 weeks, 13 patients for 12 weeks and four patients for 16 weeks. Fifty‐five per cent of patients had genotype 1, 27% had genotype 2, 15% had genotype 3 and 4% had genotype 4, and none had genotype 5 or 6 infection. The SVR12 rate was 97% (98/101, 95% confidence interval, 91.6‐99.0). No patients experienced virologic failure. Adverse events (AEs) reported in at least 5% of the patients were pruritus, bronchitis, hypertension and generalized pruritus. Serious AEs were reported in 12% of patients; none related to study drug. Conclusions: G/P treatment yielded high SVR12 rates irrespective of the presence of stage 3b, 4 or 5 CKD. No safety signals were detected. Clinicaltrials.gov identifier: This Phase 3 clinical trial was funded by AbbVie and registered with clinicaltrials.gov as NCT03069365 (EXPEDITION‐5). [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

37. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir

Author

Schnell, Gretja, primary, Krishnan, Preethi, additional, Tripathi, Rakesh, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Irvin, Michelle, additional, Dekhtyar, Tatyana, additional, Lu, Liangjun, additional, Ng, Teresa I., additional, Xie, Wangang, additional, Pilot-Matias, Tami, additional, and Collins, Christine, additional

Published
2018
Full Text
View/download PDF

38. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Author

Krishnan, Preethi, primary, Pilot-Matias, Tami, additional, Schnell, Gretja, additional, Tripathi, Rakesh, additional, Ng, Teresa I., additional, Reisch, Thomas, additional, Beyer, Jill, additional, Dekhtyar, Tatyana, additional, Irvin, Michelle, additional, Xie, Wangang, additional, Larsen, Lois, additional, Mensa, Federico J., additional, and Collins, Christine, additional

Published
2018
Full Text
View/download PDF

39. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

Author

Grebely, Jason, primary, Puoti, Massimo, additional, Wedemeyer, Heiner, additional, Cooper, Curtis, additional, Sulkowski, Mark S, additional, Foster, Graham R, additional, Berg, Thomas, additional, Villa, Erica, additional, Rodriguez-Perez, Federico, additional, Wyles, David L, additional, Schnell, Gretja, additional, Alami, Negar N, additional, Zhang, Zhenzhen, additional, Dumas, Emily, additional, and Dore, Gregory J, additional

Published
2018
Full Text
View/download PDF

40. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Author

Ng, Teresa, primary, Pilot-Matias, Tami, additional, Tripathi, Rakesh, additional, Schnell, Gretja, additional, Krishnan, Preethi, additional, Reisch, Thomas, additional, Beyer, Jill, additional, Dekhtyar, Tatyana, additional, Irvin, Michelle, additional, Lu, Liangjun, additional, Asatryan, Armen, additional, Campbell, Andrew, additional, Yao, Betty, additional, Lovell, Sandra, additional, Mensa, Federico, additional, Lawitz, Eric, additional, Kort, Jens, additional, and Collins, Christine, additional

Published
2018
Full Text
View/download PDF

41. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

Author

Krishnan, Preethi, primary, Schnell, Gretja, additional, Tripathi, Rakesh, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Dekhtyar, Tatyana, additional, Irvin, Michelle, additional, Xie, Wangang, additional, Fu, Bo, additional, Burroughs, Margaret, additional, Redman, Rebecca, additional, Kumada, Hiromitsu, additional, Chayama, Kazuaki, additional, Collins, Christine, additional, and Pilot-Matias, Tami, additional

Published
2018
Full Text
View/download PDF

42. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

Author

Ng, Teresa I., primary, Tripathi, Rakesh, additional, Reisch, Thomas, additional, Lu, Liangjun, additional, Middleton, Timothy, additional, Hopkins, Todd A., additional, Pithawalla, Ron, additional, Irvin, Michelle, additional, Dekhtyar, Tatyana, additional, Krishnan, Preethi, additional, Schnell, Gretja, additional, Beyer, Jill, additional, McDaniel, Keith F., additional, Ma, Jun, additional, Wang, Guoqiang, additional, Jiang, Li-Juan, additional, Or, Yat Sun, additional, Kempf, Dale, additional, Pilot-Matias, Tami, additional, and Collins, Christine, additional

Published
2018
Full Text
View/download PDF

43. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

Author

Schnell, Gretja, primary, Tripathi, Rakesh, additional, Krishnan, Preethi, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Irvin, Michelle, additional, Dekhtyar, Tatyana, additional, Setze, Carolyn, additional, Rodrigues-Jr, Lino, additional, Alves, Katia, additional, Burroughs, Margaret, additional, Redman, Rebecca, additional, Chayama, Kazuaki, additional, Kumada, Hiromitsu, additional, Collins, Christine, additional, and Pilot-Matias, Tami, additional

Published
2017
Full Text
View/download PDF

44. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Author

Ng, Teresa I., primary, Krishnan, Preethi, additional, Pilot-Matias, Tami, additional, Kati, Warren, additional, Schnell, Gretja, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Lu, Liangjun, additional, Dekhtyar, Tatyana, additional, Irvin, Michelle, additional, Tripathi, Rakesh, additional, Maring, Clarence, additional, Randolph, John T., additional, Wagner, Rolf, additional, and Collins, Christine, additional

Published
2017
Full Text
View/download PDF

45. Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1a and GT1b-Infected Patients

Author

Sarrazin, Christoph, primary, Sulkowski, Mark S., additional, Krishnan, Preethi, additional, Tripathi, Rakesh, additional, Schnell, Gretja, additional, Xie, Yan, additional, Cohen, Daniel E., additional, Trinh, Roger, additional, Rodrigues, Lino, additional, Luo, Yan, additional, Shulman, Nancy S., additional, Pilot-Matias, Tami, additional, and Collins, Christine, additional

Published
2016
Full Text
View/download PDF

46. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

Author

Krishnan, Preethi, primary, Schnell, Gretja, additional, Tripathi, Rakesh, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Zhang, Xinyan, additional, Setze, Carolyn, additional, Rodrigues, Lino, additional, Burroughs, Margaret, additional, Redman, Rebecca, additional, Chayama, Kazuaki, additional, Kumada, Hiromitsu, additional, Collins, Christine, additional, and Pilot-Matias, Tami, additional

Published
2016
Full Text
View/download PDF

47. Analysis of Hepatitis C Virus (HCV) Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next-Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

Author

Ng, Teresa, primary, Pilot-Matias, Tami, additional, Tripathi, Rakesh, additional, Schnell, Gretja, additional, Reisch, Thomas, additional, Beyer, Jill, additional, Dekhtyar, Tanya, additional, Wang, Stanley, additional, Mensa, Federico, additional, Kort, Jens, additional, and Collins, Christine, additional

Published
2016
Full Text
View/download PDF

48. Correction: Hepatitis C Virus Pathogen Associated Molecular Pattern (PAMP) Triggers Production of Lambda-Interferons by Human Plasmacytoid Dendritic Cells

Author

Stone, Amy E. L., Giugliano, Silvia, Schnell, Gretja, Cheng, Linling, Leahy, Katelyn F., Golden-Mason, Lucy, Gale, Michael, and Rosen, Hugo R.

Subjects
lcsh:Immunologic diseases. Allergy, lcsh:Biology (General), Virology, Immunology, Genetics, Correction, Parasitology, lcsh:RC581-607, lcsh:QH301-705.5, Molecular Biology, Microbiology
Published
2013
Full Text
View/download PDF

49. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir

Author

Schnell, Gretja, primary, Tripathi, Rakesh, additional, Beyer, Jill, additional, Reisch, Thomas, additional, Krishnan, Preethi, additional, Lu, Liangjun, additional, Dekhtyar, Tatyana, additional, Hall, Coleen, additional, Vilchez, Regis A., additional, Pilot-Matias, Tami, additional, and Collins, Christine, additional

Published
2015
Full Text
View/download PDF

50. Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

Author

Krishnan, Preethi, primary, Tripathi, Rakesh, additional, Schnell, Gretja, additional, Reisch, Thomas, additional, Beyer, Jill, additional, Irvin, Michelle, additional, Xie, Wangang, additional, Larsen, Lois, additional, Cohen, Daniel, additional, Podsadecki, Thomas, additional, Pilot-Matias, Tami, additional, and Collins, Christine, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results